Alexis focuses his practice on general corporate matters, representing emerging and public companies, as well as investors and underwriters. His practice covers a variety of transactional matters – including entity formation, corporate governance, mergers & acquisitions and public offerings. During law school, Alexis participated in the Startup Law Initiative and the New Business Community Law Clinic.
Beta Bionics Announces Upsized $234.6 Million IPO, Concurrent $17 Million Private Placement
January 31, 2025
Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.
Structure Therapeutics Announces Upsized $547.4 Million Public Offering
June 7, 2024
Cooley advised Structure Therapeutics (Nasdaq: GPCR), a global, clinical-stage biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, on its upsized $547.4 million underwritten public offering.
AGS Announces Definitive Agreement to Be Acquired by Brightstar Capital Partners for $1.1 Billion
May 9, 2024
Cooley advised PlayAGS, a global gaming supplier of high-performing slots, tables and interactive products, on its definitive agreement to be acquired by the affiliates of Brightstar Capital Partners for $1.1 billion.
Cidara Therapeutics Announces Concurrent Reacquisition of IP Rights to CD388, $240 Million PIPE Financing
May 1, 2024
Cooley advised Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, on its concurrent $240 million private placement financing and definitive agreement with Janssen Pharmaceuticals, a Johnson & Johnson Company, to reacquire the exclusive global development and commercial rights to CD388.